Efficacy of Phycocyanin and Palmitoylethanolamide for the Treatment of Chronic Prostatitis Symptoms
CompletedPhase 4NCT07013890
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a bothering condition characterized by pain localized to the pelvic, perineal and/or genital area and lower urinary tract symptoms (LUTS). Phytotherapy, which involves the combination of two or more active compounds, can be used to treat this challenging condition. The aim of this study was to investigate the role of an association of phycocyanin (PC) and palmitoylethanolamide (PEA) and selenium (FICOXPEA®) in male patients affected by CP/CPPS. The main questions the present study aims to answer are: * Does FICOXPEA® enhance quality of life of CPP/CPPS patients? * Does it help reducing pain symptoms of CPP/CPPS patients? Researchers will investigate whether FICOXPEA® works to treat CPP/CPPS symptoms, so its efficacy, but also its tolerability and adherence to therapy. Participants will: * Take FICOXPEA® once a day for 30 days; * Visit the clinic for follow-up visits at 1 and 3 months; * Answer validated questionnaires and declare potential adverse events at follow-up visits.
Study details
- Official title
- Effectiveness and Safety of an Association of Phycocyanin and Palmitoylethanolamide in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Observational Multicentric Study
- Conditions
- Chronic Prostatitis (CP)
- Chronic Prostatitis With Chronic Pelvic Pain Syndrome
- Chronic Prostatitis/ Pelvic Pain Syndrome
- Interventions
- Drug: FICOXPEA® is an oral combination of Phycocyanin, Palmitoylethanolamide and selenium
- Sponsor
- Clinica Urologica Molinette - Città della Saliute e della Scienza
- Collaborators
- A.O.U. Città della Salute e della Scienza - Molinette Hospital
- Start date
- 2022-11-02
- Primary completion
- 2023-08-15
- Sex
- Male
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Italy
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * adult male patients (aged \>18 years) * clinical affection by CP/CPPS with symptoms that persisted for ≥ 3 months; * PSA values of 4 to 10 ng/ml (at least 2 determinations) * patients must have completed diagnostic work-up, such as multiparametric prostate MRI (evidence level 1a according to EAU guidelines) with or without subsequent prostate biopsy (according to the diagnostic flow-chart depicted by EAU international guidelines). Exclusion Criteria: * patients with previous diagnosis of prostate cancer * patients who underwent previous low urinary tract surgery * patients who underwent previous intravescical chemotherapy * patients with acute bacterial prostatitis * diagnostic work-up for prostate cancer not completed * patients having antibiotic therapy or specific chronic prostatis treatment (phytotherapy included) or benign prostatic iperplasia treatment (e.g. alpha litics) at the time of the recruitment or finished less than a month before
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07013890